Australia
Cellmid renews board to align with consumer health growth strategy
Cellmid Limited (ASX:CDY) has made changes to its board and senior management following the divestment of its Lyramid biotech assets to focus on the Advangen consumer health business.
Sarah Eck-Thompson is a consumer brand specialist with expertise in experiential marketing and has been nominated as alternate director to Dennis Eck, her father, effective November 30, 2020.
Independent director Dr Fintan Walton will retire by rotation at the Annual General Meeting on November 30, 2020, and will not stand for re-election while Lyramid CEO Bart Wuurman has resigned effective November 30, having completed his mandate to develop the strategy and prepare the company for divestment.
“Instrumental in transformation”[hhmc]
Cellmid’s independent chairman Dr David King has advised the company of his intention to resign from the board, and will consequently not stand for re-election at the AGM.
Cellmid chief executive officer Maria Halasz said: “David has been instrumental in Cellmid’s transfo..
-
Tech7 months ago
Search engine startup asks users to be the customer, not the product
-
Europe4 weeks ago
Covid: Flights shut down as EU discusses UK virus threat
-
Health4 weeks ago
Spain ‘to register’ those who refuse to have Covid-19 vaccine
-
Sports4 years ago
Boxing continues to knock itself out with bewildering, incorrect decisions
-
Sports4 years ago
Phillies’ Aaron Altherr makes mind-boggling barehanded play
-
Europe2 months ago
45 arrested across Europe and Brazil as authorities seize ‘record haul’ of cocaine
-
Sports4 years ago
Steph Curry finally got the contract he deserves from the Warriors
-
latest news7 months ago
Creepy technologies invade European post-pandemic workplaces